title: Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients.
abstract: Duloxetine is a potent and selective inhibitor of serotonin and norepinephrine reuptake with weak activity on dopamine reuptake. Enzymes involved in duloxetine metabolism are cytochrome P450 isoenzymes (CYP) CYP1A2 and to a lesser extent CYP2D6 whereas the selective serotonin reuptake inhibitor Fluvoxamine is known to be a potent inhibitor of CYP1A2. Changes in plasma levels of duloxetine revealing pharmacokinetic interactions with fluvoxamine, clinical effects and adverse effects of adding fluvoxamine in thirteen patients with a steady-state duloxetine treatment by intraindividual comparisons were analyzed in this retrospective survey. Patients had been treated with duloxetine under steady-state conditions until fluvoxamine was added. Plasma duloxetine levels were measured at steady state of different daily doses due to lacking experience with the combination of DLX and FLX. Adding 25 mg of fluvoxamine (FLX) per day to a steady-state treatment with 30 mg of duloxetine (DLX) in 8 patients led to an average increase of duloxetine plasma levels that was 3-fold with a magnitude of 50-506%. Our findings indicate that duloxetine plasma levels can be enhanced by a potent CYP1A2 inhibition by FLX and that DLX, even in higher plasma levels, seems to be well tolerated. The use of combined treatments, however, underscores the importance of understanding pharmacokinetic interactions.
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen , Germany. mpaulzen@ukaachen.de
authors: M
authors: M
authors: Paulzen
authors: A
authors: A
authors: Finkelmeyer
authors: M
authors: M
authors: Grözinger
mesh_terms: D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D003866:Depressive Disorder / Q000097:blood* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D000068736:Duloxetine Hydrochloride; D005260:Female; D016666:Fluvoxamine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D038801:International Classification of Diseases; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013876:Thiophenes / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics
chemical_list: D018687:Antidepressive Agents, Second-Generation; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride; D016666:Fluvoxamine